Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
The Economy
Bank Stresses Equivalent to an Interest Rate Hike: Powell
The Fed chair said it was too soon to tell how monetary policy should respond to recent banking turmoil.
By
Vincent Ryan
| March 23, 2023
Read More
Resources
Reports
Reports
2023
2022
Featured
The Economy
Bank Stresses Equivalent to an Interest Rate Hike: Powell
The Fed chair said it was too soon to tell how monetary policy should respond to recent banking turmoil.
By
Vincent Ryan
| March 23, 2023
Read More
Sign Up
Menu
Reports
2023
2022
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
Sign Up
Sponsored by
Pharmaceutical industry
Risk & Compliance
Mylan Underpaid U.S. on Rebates for EpiPen
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
By
Matthew Heller
| October 6, 2016
Read More
Strategy
Merck Buys Cough Drug Developer for $1.25B
The acquisition of Afferent Pharmaceuticals gives Merck access to a drug candidate for treating neurogenic conditions including chronic cough.
By
Katie Kuehner-Hebert
| June 10, 2016
Read More
Strategy
Pfizer Adds Eczema Gel With $5B Anacor Deal
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
By
Katie Kuehner-Hebert
| May 16, 2016
Read More
Risk & Compliance
Biotech CFO Accused of Misleading Investors
The ex-CFO of Aveo Pharmaceuticals and other top executives allegedly failed to disclose FDA concerns about an experimental cancer drug.
By
Matthew Heller
| March 30, 2016
Read More
Strategy
Ireland’s Shire Buys Baxalta for $32 Billion
The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
By
Katie Kuehner-Hebert
| January 11, 2016
Read More
People
Valeant Stock Falls 10% on News of CEO’s Illness
Michael Pearson, who was hospitalized with pneumonia, has been trying to win back investor trust amid concerns over Valeant's pricing practices.
By
Katie Kuehner-Hebert
| December 28, 2015
Read More
Risk & Compliance
Novartis Settles Kickback Charges for $370M
The Swiss drug maker allegedly turned specialty pharmacies into a "biased sales force" for its medications.
By
Matthew Heller
| November 20, 2015
Read More
Strategy
Shire to Buy Rival Drug Maker Dyax for $5.9B
The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
By
Matthew Heller
| November 2, 2015
Read More
Strategy
Cipla Buys Two U.S. Pharma Firms for $550M
The acquisitions give the Indian drug maker its first manufacturing plant in the U.S. and an opportunity to build U.S. market share.
By
Katie Kuehner-Hebert
| September 4, 2015
Read More
Strategy
Teva to Buy Allergan’s Generic Drug Unit for $40.5B
If the deal is approved, Teva says the combined company would have revenue of about $26 billion and EBITDA of $9.5 billion in 2016.
By
Katie Kuehner-Hebert
| July 27, 2015
Read More